Category: In Conversation With
-
Sanofi’s ASH 2025: Redefining rare blood disorder care
Sanofi’s head of rare diseases, Jeff Schaffnit, outlines the company’s dual approach: redefining hemophilia care and pioneering immune modulation for rare blood disorders.
-
AVITA’s spray on skin cells slashes pain and hospital stays
Dr. Victoria Miles discusses how RECELL, which creates an autologous skin cell suspension, is reshaping burn care, access, and outcomes.
-
The $1 trillion blind spot: Bridging the gap in women’s health
Dr. Christian Tidona, founder and CEO of BioMed X, on why women’s health is critically underfunded and how a new initiative aims to change that.
-
mRNA technology set to revolutionize snakebite treatment
UK researcher Prof. Vaiyapuri discusses how Covid vaccine technology could soon neutralize deadly snake venom, preventing death and disability for millions.
-
NanoTemper’s vision: Seeing molecules in real time
The company’s CEO talks about the new tech that reveals hidden molecular dynamics, and how the recent acquisition fits into the company’s overall vision.
-
Cultivating cognitive health and calm in an anxious world
Gardening isn’t just a hobby; it’s science-backed therapy for the brain. Gardenuity CEO talks about how it supports patients & caregivers navigating memory loss.
-
Beyond animal models: The new FDA human-first drug development framework
Dr Greg Tietjen, CEO of Revalia Bio, discusses the FDA’s push for human-first data and how it’s reshaping the entire drug development pipeline.
-
Amgen’s new data reinforce weight regain after GLP-1 discontinuation
Amgen’s exec and study’s author explain that data shows stopping GLP-1s leads to weight regain, while managing LDL-C significantly reduces cardiovascular event risk.
-
Conquering aging: A bold bid to fix the body’s interconnected systems
Unlimited Bio’s CEO discusses their attempt to achieve something never done before: combining multiple gene therapies in healthy individuals to reverse the ravages of time.
-
Aphaia’s coated-glucose platform: A new approach to obesity treatment
Harnessing gut physiology, Aphaia Pharma plans to chart a safer, more natural path to lasting weight control.
-
UEGW 2025: AbbVie bolsters IBD data for Rinvoq and Skyrizi
New data and lead investigators also reinforce the importance of treating beyond symptoms in Crohn’s disease and ulcerative colitis.
-
Smarter Trials: Inside Vivalink’s integrated RPM revolution
Vivalink’s Mariel Fabro talks about how integrated remote patient monitoring (RPM) is reshaping decentralized clinical trials.
Latest posts
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
Urologic Health secures $11 million for non-invasive bladder monitoring
Urologic Health raises $11million seed funding to advance a catheter-free bladder monitoring platform toward FDA clearance and US market entry.
-
Novo Nordisk’s denecimig cuts bleeding in hemophilia A regardless of inhibitors
Phase III trial shows once‑monthly and once‑weekly denecimig (Mim8) significantly reduces annualized bleeding rate versus standard care, with up to 95% of patients bleed‑free.
-
Beyond the Snapshot: Continuous physiologic monitoring in clinical trials
Vivalink’s CEO discusses how continuous physiologic monitoring is transitioning from a niche tool for early-stage feasibility studies to a core component of late-stage drug development.